Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Truncated Isoform of Somatostatin Receptor5 (sst5TMD4) Is Associated with Poorly Differentiated Thyroid Cancer
Manel Puig‐Domingo, Raúl M. Luque, Jordi L. Reverter, et al.
PLoS ONE (2014) Vol. 9, Iss. 1, pp. e85527-e85527
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
Thomas Günther, Giovanni Tulipano, Pascal Dournaud, et al.
Pharmacological Reviews (2018) Vol. 70, Iss. 4, pp. 763-835
Open Access | Times Cited: 208
Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas
Raúl M. Luque, Alejandro Ibáñez‐Costa, Leonardo Vieira Neto, et al.
Cancer Letters (2015) Vol. 359, Iss. 2, pp. 299-306
Open Access | Times Cited: 83
Treatment of acromegaly in the era of personalized and predictive medicine
Manel Puig‐Domingo
Clinical Endocrinology (2015) Vol. 83, Iss. 1, pp. 3-14
Open Access | Times Cited: 70
The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer
Daniel Hormaechea‐Agulla, Juan M. Jiménez‐Vacas, Enrique Gómez‐Gómez, et al.
The FASEB Journal (2017) Vol. 31, Iss. 11, pp. 4682-4696
Closed Access | Times Cited: 47
Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors
Miguel Sampedro‐Núñez, Raúl M. Luque, Ana M. Ramos‐Leví, et al.
Oncotarget (2015) Vol. 7, Iss. 6, pp. 6593-6608
Open Access | Times Cited: 41
Splicing Machinery is Dysregulated in Pituitary Neuroendocrine Tumors and is Associated with Aggressiveness Features
Mari C. Vázquez‐Borrego, Antonio C. Fuentes-Fayos, Eva Venegas‐Moreno, et al.
Cancers (2019) Vol. 11, Iss. 10, pp. 1439-1439
Open Access | Times Cited: 38
In1-ghrelin, a splice variant of ghrelin gene, is associated with the evolution and aggressiveness of human neuroendocrine tumors: Evidence from clinical, cellular and molecular parameters
Raúl M. Luque, Miguel Sampedro‐Núñez, Manuel D. Gahete, et al.
Oncotarget (2015) Vol. 6, Iss. 23, pp. 19619-19633
Open Access | Times Cited: 33
BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas
Alejandro Ibáñez‐Costa, Laura M. López‐Sánchez, Manuel D. Gahete, et al.
Scientific Reports (2017) Vol. 7, Iss. 1
Open Access | Times Cited: 30
Management of aggressive growth hormone secreting pituitary adenomas
Daniel A. Donoho, Namrata Bose, Gabriel Zada, et al.
Pituitary (2016) Vol. 20, Iss. 1, pp. 169-178
Closed Access | Times Cited: 29
Expression of somatostatin receptor 2A in medullary thyroid carcinoma is associated with lymph node metastasis
Merima Herac, Bruno Niederle, Markus Raderer, et al.
Apmis (2016) Vol. 124, Iss. 10, pp. 839-845
Closed Access | Times Cited: 26
Peptides derived from the extracellular domain of the somatostatin receptor splicing variant SST5TMD4 increase malignancy in multiple cancer cell types
Mercedes del Río-Moreno, Emilia Alors‐Pérez, Patricia Borges de Souza, et al.
Translational research (2019) Vol. 211, pp. 147-160
Open Access | Times Cited: 22
Dysregulation of splicing variants and spliceosome components in breast cancer
Manuel D. Gahete, Natalia Hermán‐Sánchez, Antonio C. Fuentes-Fayos, et al.
Endocrine Related Cancer (2022) Vol. 29, Iss. 9, pp. R123-R142
Open Access | Times Cited: 12
The expression of the truncated isoform of somatostatin receptor subtype 5 associates with aggressiveness in medullary thyroid carcinoma cells
Daniela Molè, Erica Gentilin, Alejandro Ibáñez‐Costa, et al.
Endocrine (2015) Vol. 50, Iss. 2, pp. 442-452
Closed Access | Times Cited: 19
The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients
Manuel D. Gahete, David Rincon Fernandez Pacheco, Mario Durán‐Prado, et al.
Oncotarget (2016) Vol. 7, Iss. 37, pp. 60110-60122
Open Access | Times Cited: 19
The components of somatostatin and ghrelin systems are altered in neuroendocrine lung carcinoids and associated to clinical-histological features
Aura D. Herrera‐Martínez, Manuel D. Gahete, Rafael Sánchez‐Sánchez, et al.
Lung Cancer (2017) Vol. 109, pp. 128-136
Closed Access | Times Cited: 16
Dietary fat alters the expression of cortistatin and ghrelin systems in the PBMCs of elderly subjects: Putative implications in the postprandial inflammatory response
Manuel D. Gahete, Raúl M. Luque, Elena M. Yubero‐Serrano, et al.
Molecular Nutrition & Food Research (2014) Vol. 58, Iss. 9, pp. 1897-1906
Closed Access | Times Cited: 15
Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours
Jorge Barriuso, Ana Custodio, Ruth Afonso, et al.
Cancer Treatment Reviews (2018) Vol. 70, pp. 209-222
Closed Access | Times Cited: 14
Cuproptosis-related lncRNAs predict prognosis and immune response of thyroid carcinoma
Yinli Shi, Pei Sheng, Ming Guo, et al.
Frontiers in Genetics (2023) Vol. 14
Open Access | Times Cited: 4
Altered CELF4 splicing factor enhances pancreatic neuroendocrine tumors aggressiveness influencing mTOR and everolimus response
Emilia Alors‐Pérez, Sergio Pedraza‐Arévalo, Ricardo Blázquez‐Encinas, et al.
Molecular Therapy — Nucleic Acids (2023) Vol. 35, Iss. 1, pp. 102090-102090
Open Access | Times Cited: 4
Neuronostatin exerts actions on pituitary that are unique from its sibling peptide somatostatin
Raúl M. Luque, Rhonda D. Kineman
Journal of Endocrinology (2018) Vol. 237, Iss. 3, pp. 217-227
Open Access | Times Cited: 12
Somatostatin Receptor Splicing Variant sst5TMD4 Overexpression in Glioblastoma Is Associated with Poor Survival, Increased Aggressiveness Features, and Somatostatin Analogs Resistance
Antonio C. Fuentes-Fayos, Miguel E. G-García, Jesús M. Pérez‐Gómez, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1143-1143
Open Access | Times Cited: 7
The uprise of RNA biology in neuroendocrine neoplasms: altered splicing and RNA species unveil translational opportunities
Ricardo Blázquez‐Encinas, María Trinidad Moreno-Montilla, Víctor García-Vioque, et al.
Reviews in Endocrine and Metabolic Disorders (2022) Vol. 24, Iss. 2, pp. 267-282
Open Access | Times Cited: 7
Unleashing the Diagnostic, Prognostic and Therapeutic Potential of the Neuronostatin/GPR107 System in Prostate Cancer
Prudencio Sáez-Martínez, Juan M. Jiménez‐Vacas, Antonio J. León‐González, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 6, pp. 1703-1703
Open Access | Times Cited: 9
Is receptor profiling useful for predicting pituitary therapy?
Mónica Marazuela, Ana M. Ramos‐Leví, Patricia Borges de Souza, et al.
European Journal of Endocrinology (2018) Vol. 179, Iss. 5, pp. D15-D25
Open Access | Times Cited: 8
Theoretical analysis of somatostatin receptor 5 with antagonists and agonists for the treatment of neuroendocrine tumors
Santhosh Kumar Nagarajan, Sathya Babu, Thirumurthy Madhavan
Molecular Diversity (2017) Vol. 21, Iss. 2, pp. 367-384
Closed Access | Times Cited: 6
Page 1 - Next Page

Scroll to top